Immunocytokines with target cell–restricted IL-15 activity for treatment of B cell malignancies
Latifa Zekri,Ilona Hagelstein,Melanie Märklin,Boris Klimovich,Mary Christie,Cornelia Lindner,Sofie Kämereit,Nisha Prakash,Stefanie Müller,Sophie Stotz,Andreas Maurer,Carsten Greve,Bastian Schmied,Daniel Atar,Hans-Georg Rammensee,Gundram Jung,Helmut R Salih,Helmut R. Salih
DOI: https://doi.org/10.1126/scitranslmed.adh1988
IF: 17.1
2024-03-07
Science Translational Medicine
Abstract:Despite the advances in cancer treatment achieved, for example, by the CD20 antibody rituximab, an urgent medical need remains to optimize the capacity of such antibodies to induce antibody-dependent cellular cytotoxicity (ADCC) that determines therapeutic efficacy. The cytokine IL-15 stimulates proliferation, activation, and cytolytic capacity of NK cells, but broad clinical use is prevented by short half-life, poor accumulation at the tumor site, and severe toxicity due to unspecific immune activation. We here report modified immunocytokines consisting of Fc-optimized CD19 and CD20 antibodies fused to an IL-15 moiety comprising an L45E-E46K double mutation (MIC + format). The E46K mutation abrogated binding to IL-15Rα, thereby enabling substitution of physiological trans-presentation by target binding and thus conditional IL-15Rβγ stimulation, whereas the L45E mutation optimized IL-15Rβγ agonism and producibility. In vitro analysis of NK activation, anti-leukemia reactivity, and toxicity using autologous and allogeneic B cells confirmed target-dependent function of MIC + constructs. Compared with Fc-optimized CD19 and CD20 antibodies, MIC + constructs mediated superior target cell killing and NK cell proliferation. Mouse models using luciferase-expressing human NALM-6 lymphoma cells, patient acute lymphoblastic leukemia (ALL) cells, and murine EL-4 lymphoma cells transduced with human CD19/CD20 as targets and human and murine NK cells as effectors, respectively, confirmed superior and target-dependent anti-leukemic activity. In summary, MIC + constructs combine the benefits of Fc-optimized antibodies and IL-15 cytokine activity and mediate superior NK cell immunity with potentially reduced side effects. They thus constitute a promising new immunotherapeutic approach shown here for B cell malignancies.
cell biology,medicine, research & experimental